Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018

Slides:

Advertisements

Similar presentations

Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.

Advertisements

Update of Anemia management in chronic kidney disease What is still missing.

Anemia an enigma in chronic kidney disease Mohammad Asgar Khan, MD.

Journal Club EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events – EVOLVE NEJM Dec 2012 Yuvaraj Thangaraj, M.D. Nephrology Fellow Division.

 Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:

ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.

Intravenous Iron Supplementation and Chronic Kidney Disease Chloe Bierbower December 2, 2013.

NKF-KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease UPDATE OF HEMOGLOBIN TARGET Am.J.Kidney.Dis.

Hemoglobin A 1c in Hemodialysis Patients Source: Ix JH. Hemoglobin A1c in hemodialysis patients: Should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539–1541.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 3: Clinical Indicators and Preventive Care.

Secondary Hyperparathyroidism in CKD: Usefulness of VDR Agonists Reference: Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin d.

Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.

Oral Phosphate Binders in Patients with Kidney Failure

Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015

Medical Directorate, National Kidney Foundation, Singapore

Algorithm for management of anemia of CKD in adults

Sergey V. Veretennikov and Michael J. Campbell, MD

LDL cholesterol in CKD—to treat or not to treat?

Claudia Beals, MD John Detesco Erdal Sarac, MD FACP FASN

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

The ECHO Observational Study

The IDEAL Study Reference

Algorithm for iron therapy in management of anemia of CKD

Introduction CKD-MBD. Introduction CKD-MBD Regulation of PTH Secretion.

The Latest Lipid Guidelines:

Volume 67, Pages S1-S7 (June 2005)

Chapter 2: Clinical Indicators and Preventive Care

Chronic kidney disease and pre-dialysis

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

New and Emerging Management Options for Anemia in CKD

An Endocrinology Clinic in Dyslipidemia

At The Cutting Edge of Developments in the Management of Hyperkalemia

CKD Complications By Alaina Darby.

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations.

Addressing Iron Deficiency in Chronic HF

Iron Deficiency Anemia

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

American Journal of Kidney Diseases

A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients.

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.

Obstacles and Advances in Anemia Management in Patients With CKD

Volume 2: End-Stage Renal Disease

Volume 88, Issue 5, Pages (November 2015)

Volume 90, Issue 5, Pages (November 2016)

At The Cutting Edge of Developments in the Management of Hyperkalemia

Iron Deficiency Anemia

Managing CKD-Associated Anemia in Challenging Patients

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Meeting the challenges of the new K/DOQI guidelines

Chapter 2: Use of iron to treat anemia in CKD

Elevated Admission Plasma Glucose Following ACS

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Deprescribing Calcium-Based Phosphorus Binders in Dialysis Patients

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.

LDL cholesterol in CKD—to treat or not to treat?

Volume 68, Issue 6, Pages (December 2005)

Conclusion and Future Direction:

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target American.

Volume 55, Issue 5, Pages (May 1999)

Recent developments in the management of secondary hyperparathyroidism

Volume 62, Issue 6, Pages (December 2002)

Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation A.K. Singh, D.W. Coyne,

Anemia Explored.

Lipids, the Heart, and the Kidney

Challenges and Emerging Solutions in Anemia Management Explored

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

CKD Is a Global Burden With Major Implications

Presentation transcript:

Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018

Randomized Trial of Ferric Citrate in Advanced CKD

Multiple Mechanisms Related to Mineral Metabolism and Anemia Contribute to CV Events in CKD

Elevated Serum Potassium Is Associated With an Increased Risk for Dialysis

Ferric Citrate in Advanced CKD Rationale for Study

Ferric Citrate in Advanced CKD Study Schema

Patient Disposition

Modified Intent to Treat Hemoglobin, TSAT, Ferritin

Modified Intent to Treat Phosphate

Modified Intent to Treat: PTH, FGF23, and 1,25-OH Vitamin D

Time to Dialysis, Death, or Transplant

Conclusions of the Study

New Methods of Anemia Management in CKD

Evolution of CKD Anemia Treatment

HIF-PHIs in Clinical Development for the Treatment of Anemia

HIF-PHI

Other Oral Iron Formulations for Correcting Anemia

Safety of Low vs High Dose IV Iron

PIVOTAL Trial Proactive IV Iron Therapy in Hemodialysis Patients

Clinical Implications of Recent Data in Managing Anemia in CKD

Clinical Implications of Ferric Citrate Study

Survival According to Phosphate Levels Relative to KDOQI Guidelines in Patients With Non-Dialysis Dependent CKD

Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

HIF Stabilizers (HIF-PHIs)

Iron Management

Abbreviations